Northern Virginia – A team from global law firm Hogan Lovells has advised Daiichi Sankyo Company, Limited in its global collaboration to develop and commercialize three of its DXd antibody-drug conjugate (ADC) candidates, patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).
Under the transaction, Daiichi Sankyo will receive upfront payments of US$4 billion, continuation payments of US$1.5 billion over the next 24 months, and payments totaling an additional US$5.5 billion for each DXd ADC contingent upon the achievement of future sales milestones, for a total potential consideration of up to US$22 billion.
The Hogan Lovells team was led by Northern Virginia partner Cullen Taylor and senior associate Hank Watsky. They were supported by partners Mark Weinstein (New York), Lauren Battaglia (Washington, D.C.), Scott Loughlin (Washington, D.C.), and Frederick Ch’en (Tokyo); counsels Ilana Kattan (Washington, D.C.) and Anishiya Abrol (Washington, D.C.); senior associate Khaled Mowad (Washington, D.C.); and associates MK Barker (Northern Virginia), Benjamin Kim (Northern Virginia), Ashley Ifeadike (Washington, D.C.), Elizabeth Adams (Washington, D.C.), and Sayuri Mori (Tokyo).
